Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 11/20 | 0.51 |
| ▸ | PRKCH | P24723 | 11/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 11/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 11/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 10/20 | 0.51 |
| ▸ | PRKCB | P05771 | 10/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.51 |
| ▸ | CCND1 | P24385 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.51 |
| ▸ | PRKCG | P05129 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | PRKCI | P41743 | 2/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.51 |
| ▸ | PRKACG | P22612 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349685 | 0.88 | KDR (0.51) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL2340281 | 0.82 | GSK3B (0.43) | PRKCAPRKCQPRKCBGSK3BGSK3A | |
| SCHEMBL2341048 | 0.80 | PRKCB (0.59) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL6324887 | 0.77 | PRKCB (0.51) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL6325786 | 0.77 | CDK4 (0.52) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL6335215 | 0.77 | GSK3B (0.52) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL224940 | 0.76 | CDK4 (0.61) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL6328464 | 0.74 | PRKD1 (0.52) | PRKCAPRKCHPRKCEPRKCDPRKCQ | |
| SCHEMBL2344815 | 0.74 | GSK3B (0.44) | PRKCAGSK3BSLK | |
| SCHEMBL6329959 | 0.73 | CDK4 (0.60) | PRKCAPRKCHPRKCEPRKCDPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | PRKCA 881/4885PRKCH 584/4885PRKCE 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.